Associations of seven measures of biological age acceleration with frailty and all-cause mortality among adult survivors of childhood cancer in the St. Jude Lifetime Cohort
Nat Cancer. 2024 Mar 29. doi: 10.1038/s43018-024-00745-w. Online ahead of print.ABSTRACTSurvivors of childhood cancer may experience accelerated biological aging, resulting in premature frailty and death. We used seven measures of biological age in the St. Jude Lifetime (SJLIFE) Cohort to compare biological age acceleration between the SJLIFE Cohort and the third United States National Health and Nutrition Examination Survey controls, explore trajectories of biological age according to cancer treatment and type, and test associations of biological age acceleration with frailty and death (mean follow-up of 26.5 years) among...
Source: Cancer Control - March 30, 2024 Category: Cancer & Oncology Authors: Jennifer L Guida Geehong Hyun Daniel W Belsky Gregory T Armstrong Matthew J Ehrhardt Melissa M Hudson Paige A Green Leslie L Robison Brennan P Streck Emily S Tonorezos Yutaka Yasui Carmen L Wilson Zhaoming Wang Kirsten K Ness Source Type: research
Ewing's sarcoma in adolescents and adults - 10-year experience from a tertiary cancer center in India
CONCLUSION: Treatment of EWS requires a multidisciplinary approach with radical surgery and/or radiation to control local disease and multiagent chemotherapy to control systemic disease. Long-term follow-up is essential because of disease relapse and treatment-related complications.PMID:38554302 | DOI:10.4103/jcrt.jcrt_775_22 (Source: Cell Research)
Source: Cell Research - March 30, 2024 Category: Cytology Authors: Geetha Narayanan Lakshmi H Kamala Sreejith G Nair Prakash N Purushothaman Aswin Kumar Jayasree Kattoor Source Type: research
Ewing's sarcoma in adolescents and adults - 10-year experience from a tertiary cancer center in India
CONCLUSION: Treatment of EWS requires a multidisciplinary approach with radical surgery and/or radiation to control local disease and multiagent chemotherapy to control systemic disease. Long-term follow-up is essential because of disease relapse and treatment-related complications.PMID:38554302 | DOI:10.4103/jcrt.jcrt_775_22 (Source: Cancer Control)
Source: Cancer Control - March 30, 2024 Category: Cancer & Oncology Authors: Geetha Narayanan Lakshmi H Kamala Sreejith G Nair Prakash N Purushothaman Aswin Kumar Jayasree Kattoor Source Type: research
GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma
CONCLUSIONS: Our experimental data indicate the feasibility of CAR.GD2 T-cell therapy. A phase I/II clinical trial will be conducted to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.PMID:38551501 | DOI:10.1158/1078-0432.CCR-23-1880 (Source: Cell Research)
Source: Cell Research - March 29, 2024 Category: Cytology Authors: Roselia Ciccone Concetta Quintarelli Antonio Camera Michele Pezzella Simona Caruso Simona Manni Alessio Ottaviani Marika Guercio Francesca Del Bufalo Maria Cecilia Quadraccia Domenico Orlando Stefano Di Cecca Matilde Sinibaldi Mariasole Aurigemma Laura Ia Source Type: research
GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma
CONCLUSIONS: Our experimental data indicate the feasibility of CAR.GD2 T-cell therapy. A phase I/II clinical trial will be conducted to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.PMID:38551501 | DOI:10.1158/1078-0432.CCR-23-1880 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 29, 2024 Category: Cancer & Oncology Authors: Roselia Ciccone Concetta Quintarelli Antonio Camera Michele Pezzella Simona Caruso Simona Manni Alessio Ottaviani Marika Guercio Francesca Del Bufalo Maria Cecilia Quadraccia Domenico Orlando Stefano Di Cecca Matilde Sinibaldi Mariasole Aurigemma Laura Ia Source Type: research
GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma
CONCLUSIONS: Our experimental data indicate the feasibility of CAR.GD2 T-cell therapy. A phase I/II clinical trial will be conducted to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.PMID:38551501 | DOI:10.1158/1078-0432.CCR-23-1880 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 29, 2024 Category: Cancer & Oncology Authors: Roselia Ciccone Concetta Quintarelli Antonio Camera Michele Pezzella Simona Caruso Simona Manni Alessio Ottaviani Marika Guercio Francesca Del Bufalo Maria Cecilia Quadraccia Domenico Orlando Stefano Di Cecca Matilde Sinibaldi Mariasole Aurigemma Laura Ia Source Type: research
GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma
CONCLUSIONS: Our experimental data indicate the feasibility of CAR.GD2 T-cell therapy. A phase I/II clinical trial will be conducted to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.PMID:38551501 | DOI:10.1158/1078-0432.CCR-23-1880 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 29, 2024 Category: Cancer & Oncology Authors: Roselia Ciccone Concetta Quintarelli Antonio Camera Michele Pezzella Simona Caruso Simona Manni Alessio Ottaviani Marika Guercio Francesca Del Bufalo Maria Cecilia Quadraccia Domenico Orlando Stefano Di Cecca Matilde Sinibaldi Mariasole Aurigemma Laura Ia Source Type: research
GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma
CONCLUSIONS: Our experimental data indicate the feasibility of CAR.GD2 T-cell therapy. A phase I/II clinical trial will be conducted to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.PMID:38551501 | DOI:10.1158/1078-0432.CCR-23-1880 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 29, 2024 Category: Cancer & Oncology Authors: Roselia Ciccone Concetta Quintarelli Antonio Camera Michele Pezzella Simona Caruso Simona Manni Alessio Ottaviani Marika Guercio Francesca Del Bufalo Maria Cecilia Quadraccia Domenico Orlando Stefano Di Cecca Matilde Sinibaldi Mariasole Aurigemma Laura Ia Source Type: research
Development of a value assessment framework for pediatric health technologies using multi-criteria decision analysis: expanding the value lens for funding decision-making
CONCLUSIONS: We iteratively developed a value assessment framework that captures dimensions of child-specific health and non-health gains. CATCH could improve the richness and relevance of HTA decision-making for children in Canada and comparable health systems.PMID:38548179 | DOI:10.1016/j.jval.2024.03.012 (Source: Cancer Control)
Source: Cancer Control - March 28, 2024 Category: Cancer & Oncology Authors: Cindy L Gauvreau Leighton Schreyer Paul Gibson Alicia Koo Wendy J Ungar Dean Regier Kelvin Chan Robin Hayeems Jennifer Gibson Antonia Palmer Stuart Peacock Avram E Denburg Source Type: research
Second malignant neoplasms within 5 years from first primary diagnosis in pediatric oncology patients in Canada: a population-based retrospective cohort study
This study aims to assess the incidence, characteristics, management, and outcome of children who develop SMN malignancies within 5 years of diagnosis of their initial cancer.MethodThis is a retrospective cohort study of early Second Malignant Neoplasms (SMN) in pediatric oncology patients. The Cancer in Young People – Canada (CYP-C) national pediatric cancer registry was used and reviewed pediatric patients diagnosed with their first cancer from 2000-2015.ResultsA total of 20,272 pediatric patients with a diagnosis of a first malignancy were analyzed. Of them, 0.7% were diagnosed with a SMN within the first 5 years foll...
Source: Frontiers in Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Corrigendum: Cancer data quality and harmonization in Europe: The experience of the BENCHISTA Project – International Benchmarking of Childhood Cancer Survival by Stage
(Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Cancers, Vol. 16, Pages 1297: Causes of Childhood Cancer: A Review of the Recent Literature: Part I & mdash;Childhood Factors
Cancers, Vol. 16, Pages 1297: Causes of Childhood Cancer: A Review of the Recent Literature: Part I—Childhood Factors
Cancers doi: 10.3390/cancers16071297
Authors:
Angela M. Ricci
Rebecca T. Emeny
Pamela J. Bagley
Heather B. Blunt
Mary E. Butow
Alexandra Morgan
Jennifer A. Alford-Teaster
Linda Titus
Raymond R. Walston
Judy R. Rees
Purpose: To review the childhood risk factors for pediatric cancer (diagnosis before age 20). Methods: We conducted literature searches using Ovid Medline and Scopus to find primary research studies, review articles, and meta-analyses published from 2014 to 3 M...
Source: Cancers - March 27, 2024 Category: Cancer & Oncology Authors: Angela M. Ricci Rebecca T. Emeny Pamela J. Bagley Heather B. Blunt Mary E. Butow Alexandra Morgan Jennifer A. Alford-Teaster Linda Titus Raymond R. Walston Judy R. Rees Tags: Review Source Type: research
Cancers, Vol. 16, Pages 1296: Association of Insulin-like Growth Factor-1 with Bone Mineral Density in Survivors of Childhood Acute Leukemia
In this study, we investigated bone mineral deficits in children who survived childhood acute leukemia and explored the association between the insulin-like growth factor-1 (IGF-1) level and bone mineral density (BMD). This retrospective analysis enrolled 214 patients treated for acute leukemia, measuring various factors including height, weight, body mass index (BMI), and lumbar spine BMD after the end of treatment. The study found an overall prevalence of low BMD in 15% of participants. Notably, IGF-1 levels were significantly different between patients with low BMD and those with normal BMD, and correlation analyses rev...
Source: Cancers - March 27, 2024 Category: Cancer & Oncology Authors: Seulki Kim Jae Won Yoo Jae Wook Lee Min Ho Jung Bin Cho Byng-Kyu Suh Moon Bae Ahn Nack-Gyun Chung Tags: Article Source Type: research
< em > Trans < /em > isomeric fatty acids in human milk and their role in infant health and development
Front Nutr. 2024 Mar 7;11:1379772. doi: 10.3389/fnut.2024.1379772. eCollection 2024.ABSTRACTIt is well known that long chain polyunsaturated fatty acids (LCPUFAs) play an important role in neurodevelopment in the perinatal life. The most important source of these fatty acids is the diet, however, they can also be formed in the human body from their shorter chain precursors, the essential fatty acids. Since the WHO recommends exclusive breastfeeding for the first six months after birth, the exclusive source of these fatty acids for breastfed infants is human milk, which can be influenced by the mother's diet. Unsaturated fa...
Source: Atherosclerosis - March 22, 2024 Category: Cardiology Authors: Okba Hatem Ömer Furkan Kaçar H üsna Kaya Kaçar J ózsef L Szentpéteri Tam ás Marosvölgyi Éva Szabó Source Type: research
< em > Trans < /em > isomeric fatty acids in human milk and their role in infant health and development
Front Nutr. 2024 Mar 7;11:1379772. doi: 10.3389/fnut.2024.1379772. eCollection 2024.ABSTRACTIt is well known that long chain polyunsaturated fatty acids (LCPUFAs) play an important role in neurodevelopment in the perinatal life. The most important source of these fatty acids is the diet, however, they can also be formed in the human body from their shorter chain precursors, the essential fatty acids. Since the WHO recommends exclusive breastfeeding for the first six months after birth, the exclusive source of these fatty acids for breastfed infants is human milk, which can be influenced by the mother's diet. Unsaturated fa...
Source: Atherosclerosis - March 22, 2024 Category: Cardiology Authors: Okba Hatem Ömer Furkan Kaçar H üsna Kaya Kaçar J ózsef L Szentpéteri Tam ás Marosvölgyi Éva Szabó Source Type: research
